Myovant Sciences’ (MYOV) “Buy” Rating Reaffirmed at Cowen and Company
Myovant Sciences Ltd (NASDAQ:MYOV)‘s stock had its “buy” rating reissued by research analysts at Cowen and Company in a note issued to investors on Tuesday.
Other analysts have also issued reports about the stock. Zacks Investment Research upgraded shares of Myovant Sciences from a “sell” rating to a “hold” rating in a research report on Thursday, August 31st. Evercore ISI began coverage on shares of Myovant Sciences in a research note on Wednesday, August 16th. They set an “outperform” rating for the company. One equities research analyst has rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. The company has a consensus rating of “Buy” and an average price target of $18.20.
Myovant Sciences (MYOV) traded up 1.36% on Tuesday, hitting $14.88. The stock had a trading volume of 150,312 shares. Myovant Sciences has a one year low of $10.25 and a one year high of $18.85. The stock’s 50 day moving average is $13.46 and its 200 day moving average is $13.46. The stock’s market cap is $905.36 million.
Several institutional investors and hedge funds have recently bought and sold shares of the stock. Deerfield Management Co. acquired a new position in Myovant Sciences in the 4th quarter valued at about $18,619,000. RA Capital Management LLC boosted its position in Myovant Sciences by 56.6% during the first quarter. RA Capital Management LLC now owns 2,348,422 shares of the company’s stock worth $27,570,000 after acquiring an additional 848,422 shares during the last quarter. Norges Bank acquired a new stake in Myovant Sciences during the fourth quarter worth approximately $9,763,000. Eventide Asset Management LLC acquired a new stake in Myovant Sciences during the first quarter worth approximately $3,463,000. Finally, Perceptive Advisors LLC acquired a new stake in Myovant Sciences during the fourth quarter worth approximately $2,815,000.
Myovant Sciences Company Profile
Myovant Sciences Ltd. is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for women’s health diseases and other endocrine-related disorders. Its main product candidate is Relugolix. Relugolix is an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone (GnRH) receptor antagonist that binds to and inhibits receptors in the anterior pituitary gland.
Receive News & Ratings for Myovant Sciences Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myovant Sciences Ltd and related companies with MarketBeat.com's FREE daily email newsletter.